Other

Coulter Pharmaceutical, Inc.

University of Michigan

Coulter Corporation

Neuova, LLC

Zor Pharmaceuticals, LLC

Cardiopharma, Inc.

Stephan D Glenn

Richard L Wahl

Gregory M Butchko

Mark S Kaminski

Daniel Tyree Gregory, Jr

Roy A Stimits

Paulette E Smariga

Asher Nathan

Edward O'Connell

Gregory Butchko

Daniel T Gregory

Frank Detlev Goj

Wayne L Whittingham

David P Hause

Disclosed is a method of manufacturing a cardiovascular fixed-dose combination pharmaceutical dosage form that includes an anti-hypertensive active agent, a cholesterol-lowering active agent, and optionally, an enteric-coated aspirin or platelet inhibitor. The fixed-dose combination is prepared with at least two granulation solutions that are free of citric acid and enhance the aqueous solubility of the cholesterol-lowering agent in fixed-dose combination. The active agents in the resulting dosage form, which is also free of citric acid, have the same strength and release profiles as the same active agents prepared as a single formulation.

Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture

A non-invasive, transcutaneous electrical device stimulates nerves using unpulsed, constant direct current. The device uses a constant, unpulsed direct electric current of low constant voltage and power through air core uninsulated wire coil electrodes. The device includes a switch to open or close the circuit, a fuse that serves as the automatic overload trip voltage level, and two wire coil electrodes of uninsulated wire. The coil electrodes are positioned on the forehead directly superior to the eyes proximal to the supraorbital and supratrochlear nerves and apply a direct current transcutaneously to the forehead.

Transcutaneous neural stimulation device

A method of making a consumable product containing purified embryonatedova (TSO) preferably includes steps of: storing the TSO in an acidic solution; adding a food preservative to the acidic solution to produce a preservative-acid-solution; forming a mixing solution by raising the pH of the preservative-acidic-solution to match the pH of a food substance by titrating the preservative-acidic-solution with an acid neutralizer so that the pH changes at a rate of not more than 1 pH unit per 24 hours, preferably to a pH not higher than 5.0; and producing the consumable product by combining the mixing solution and the food substance while maintaining the temperature of the consumable product between 1 degree Centigrade and 47 degrees Centigrade.

[object Object]

A method for treating a cancer, by determining a patient to have an ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 and selecting that patient for treatment, and administering to the patient an effective amount of an immunomodulating composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: (i) is extracted from bile of animals; (ii) is capable of stimulating monocytes and/or macrophages; (iii) is capable of modulating tumor necrosis factor production and/or release; (iv) contains no measurable level of IL-1&#x3b1;, IL-1&#x3b2;, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-&#x3b3;; (v) is not cytotoxic to human peripheral blood mononuclear cells; and (vi) is not an endotoxin. A method of increasing the survival rate of a cancer patient.

Use of immunomodulators for the treatment of cancer

A method for treating a cancer, by determining a patient to have an ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 and selecting that patient for treatment, and administering to the patient an effective amount of an immunomodulating composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: (i) is extracted from bile of animals; (ii) is capable of stimulating monocytes and/or macrophages; (iii) is capable of modulating tumor necrosis factor production and/or release; (iv) contains no measurable level of IL-1&#x3b1;, IL-1&#x3b2;, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-&#x3b3;; (v) is not cytotoxic to human peripheral blood mononuclear cells; and (vi) is not an endotoxin.

Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.

Radioimmunotherapy of lymphoma using anti-CD20 antibodies

Methods for the treatment of lymphoma by adminstration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.

Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy also described is a composition useful in the treatment of lymphoma.

Radioimmunotherapy of lymphoma using anti-CD20

A single filtration device containing coated filter membranes and absolute pore filters is provided in which the membranes and absolute pore filters are present in two sections of the filter device. The filter device will remove up to about 98% of the endotoxins in addition to removing viruses with an efficiency of at least 4.6.times.10.sup.5 and DNA to less than 10 picograms per 500 mg sample.

Process and apparatus for removal of DNA, viruses and endotoxins

A single filtration device containing coated filter membranes and absolute pore filters is provided in which the membranes and absolute pore filters are present in two sections of the filter device. The filter device will remove viruses, as modeled by type-C Xenotropic retrovirus, with an efficiency of at least 4.6.times.10.sup.5 ; remove DNA from levels of 10 .mu.g/sample to levels below 10 picograms per 500 mg sample of monoclonal antibody; and will remove at least 97% of some bacterial endotoxins.

Growing community of inventors

Davie, FL, United States of America

Stephan D Glenn